Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges

References

• Pulte D, Gondos A, Brenner H. Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol. 2010;21(2):335–341.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010;116(26):5818–5823. quiz 6153.
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597–1603.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485.
   PubMed Web of Science ®Google Scholar
• Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma. 2014;55(5):979–987.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Labopin M, Milpied N, et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2012;47(11):1442–1447.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–3666.
   PubMed Web of Science ®Google Scholar
• Bornhäuser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035–1044.
   PubMed Web of Science ®Google Scholar
• Jourdan E, Boiron JM, Dastugue N, et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol. 2005;23(30):7676–7684.
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2015;21(3):454–459.
   PubMed Web of Science ®Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422–433.
   PubMed Web of Science ®Google Scholar
• Othus M, Appelbaum FR, Petersdorf SH, et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant. 2015;21(3):559–564.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73(6):1720–1728.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31):4938–4945.
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555–562.
   PubMed Web of Science ®Google Scholar
• Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361(5):478–488.
   PubMed Web of Science ®Google Scholar
• Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305–334.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Rafelson WM, Reagan JL, Fast LD, et al. Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel? Leuk Lymphoma. 2017;58(11):2523–2531.
   PubMed Web of Science ®Google Scholar
• Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116(11):1908–1918.
   PubMed Web of Science ®Google Scholar
• Martínez A, Olarte I, Mergold MA, et al. mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res. 2007;31(1):33–37.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Luetkens T, Kloth B, et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol. 2011;86(11):918–922.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Mandal A, et al. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res. 2004;10(19):6544–6550.
   PubMed Web of Science ®Google Scholar
• Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40(5):377–387.
   PubMed Web of Science ®Google Scholar
• Fiegl M, Samudio I, Clise-Dwyer K, et al. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood. 2009;113(7):1504–1512.
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Kjaergaard J, Lukashev D, et al. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res. 2008;14(19):5947–5952.
   PubMed Web of Science ®Google Scholar
• Vasold J, Wagner M, Drolle H, et al. The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro. Leuk Res. 2015;39(2):257–262.
   PubMed Web of Science ®Google Scholar
• Powles RL, Russell J, Lister TA, et al. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer. 1977;35(3):265–272.
   PubMed Web of Science ®Google Scholar
• McCredie KB, Gehan EA, Freireich EJ, et al. Management of adult acute leukemia. A Southwest Oncology Group study. Cancer. 1983;52(6):958–966.
   PubMed Web of Science ®Google Scholar
• Bezwoda W, Seymour L, Ruff P. Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma. Int J Oncol. 1993;2(3):469–472.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–1311.
   PubMed Web of Science ®Google Scholar
• Meloni G, Vignetti M, Andrizzi C, et al. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leuk Lymphoma. 1996;21(5–6):429–435.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.
   PubMed Web of Science ®Google Scholar
• Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 2001;159(6):2107–2116.
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154(6):1805–1813.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–829.
   PubMed Web of Science ®Google Scholar
• McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol. 1999;77(1):1–10.
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–1217.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423–1427.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114(8):1545–1552.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501–4510.
   PubMed Web of Science ®Google Scholar
• Dolen Y, Esendagli G. Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur J Immunol. 2013;43(3):747–757.
   PubMed Web of Science ®Google Scholar
• Ozkazanc D, Yoyen-Ermis D, Tavukcuoglu E, et al. Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells. Immunology. 2016;149(4):460–471.
   PubMed Web of Science ®Google Scholar
• Daver N, Basu S, Garcia-Manero G, et al. Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML). Blood. 2016;128(22):2900.
   Web of Science ®Google Scholar
• Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232–4244.
   PubMed Web of Science ®Google Scholar
• Wendelbo Ø, Nesthus I, Sjo M, et al. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother. 2004;53(8):740–747.
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–1288.
   PubMed Web of Science ®Google Scholar
• Whiteway A, Corbett T, Anderson R, et al. Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol. 2003;120(3):442–451.
   PubMed Web of Science ®Google Scholar
• Graf M, Reif S, Hecht K, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol. 2005;84(5):287–297.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu S, Wang L, et al. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther. 2008;7(5):622–627.
   PubMed Web of Science ®Google Scholar
• Schnorfeil FM, Lichtenegger FS, Emmerig K, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93.
   PubMed Web of Science ®Google Scholar
• Greiner J, Götz M, Schneider V, et al. Specific immune responses for leukemia-associated antigens against myeloid leukemic cells are increased by immune checkpoint inhibition. Blood. 2016;128(22):4054.
   Web of Science ®Google Scholar
• Zhou Q, Munger ME, Highfill SL, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116(14):2484–2493.
   PubMed Web of Science ®Google Scholar
• Zajac M, Zaleska J, Dolnik A, et al. Analysis of the PD-1/PD-L1 axis points to association of unfavorable recurrent mutations with PD-L1 expression in AML. Blood. 2016;128(22):1685.
   Web of Science ®Google Scholar
• Yang S, Huang XJ. The poorer-risk AML, the weaker immunologic surveillance? – higher PD-L1 expression on non-APL AML cells is associated with poorer risk status according to cytogenetics and molecular abnormailties. Blood. 2016;128(22):1619.
   Web of Science ®Google Scholar
• Liu H, Park J-H, Fulton N, et al. TCR clonal evolution in AML patients in morphologic remission treated with anti-PD1 antibody, nivolumab. Blood. 2016;128(22):2325.
   Web of Science ®Google Scholar
• Greiner J, Ono Y, Hofmann S, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood. 2012;120(6):1282–1289.
   PubMed Web of Science ®Google Scholar
• Greiner J, Schneider V, Schmitt M, et al. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood. 2013;122(6):1087–1088.
   PubMed Web of Science ®Google Scholar
• Greiner J, Hofmann S, Schmitt M, et al. Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. Haematologica. 2017;102(12):e499–e501.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–182.
   PubMed Web of Science ®Google Scholar
• Re F, Arpinati M, Testoni N, et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Exp Hematol. 2002;30(2):126–134.
   PubMed Web of Science ®Google Scholar
• Albring JC, Inselmann S, Sauer T, et al. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52(2):317–320.
   PubMed Web of Science ®Google Scholar
• Pistillo MP, Tazzari PL, Palmisano GL, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood. 2003;101(1):202–209.
   PubMed Web of Science ®Google Scholar
• Laurent S, Palmisano GL, Martelli AM, et al. CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br J Haematol. 2007;136(4):597–608.
   PubMed Web of Science ®Google Scholar
• Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood. 2004;104(7):2124–2133.
   PubMed Web of Science ®Google Scholar
• Boughan KM, Chen X, Szabolcs P. Enhancing cytotoxicity of autologous T cells in AML by blockade of CTLA-4 and PD-1. Blood. 2016;128(22):4057.
   Web of Science ®Google Scholar
• Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272–1277.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Opposing roles of CD28:B7and CTLA-4:B7pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 1999;162(11):6368–6377.
   PubMed Web of Science ®Google Scholar
• Poh SL, Linn YC. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. Cancer Immunol Immunother. 2016;65(5):525–536.
   PubMed Web of Science ®Google Scholar
• Gonçalves Silva I, Gibbs BF, Bardelli M, et al. Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells. Oncotarget. 2015;6(32):33823–33833.
   PubMedGoogle Scholar
• Gonçalves Silva I, Yasinska IM, Sakhnevych SS, et al. The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017;22:44–57.
   PubMed Web of Science ®Google Scholar
• Li J, Shayan G, Avery L, et al. Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: evidence for intracellular cross talk. Oncoimmunology. 2016;5(10):e1200778.
   PubMed Web of Science ®Google Scholar
• Shin H, Blackburn SD, Intlekofer AM, et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity. 2009;31(2):309–320.
   PubMed Web of Science ®Google Scholar
• Quigley M, Pereyra F, Nilsson B, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010;16(10):1147–1151.
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225–274.
   PubMed Web of Science ®Google Scholar
• Bottino C, Castriconi R, Moretta L, et al. Cellular ligands of activating NK receptors. Trends Immunol. 2005;26(4):221–226.
   PubMed Web of Science ®Google Scholar
• Doubrovina ES, Doubrovin MM, Vider E, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol. 2003;171(12):6891–6899.
   PubMed Web of Science ®Google Scholar
• Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol. 2005;35(1):10–15.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100.
   PubMed Web of Science ®Google Scholar
• Romagné F, André P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114(13):2667–2677.
   PubMed Web of Science ®Google Scholar
• Shah N, Shpall EJ. NK antibody therapy: KIR-ative intent. Blood. 2009;114(13):2567–2568.
   PubMed Web of Science ®Google Scholar
• Berrien-Elliott MM, Jackson SR, Meyer JM, et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res. 2013;73(2):605–616.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–299.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Boder ET, Discher DE. Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site. J Biol Chem. 2007;282(3):1805–1818.
   PubMed Web of Science ®Google Scholar
• Galli S, Zlobec I, Schürch C, et al. CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis. Leuk Res. 2015;39(7):749–756.
   PubMed Web of Science ®Google Scholar
• Theocharides AP, Jin L, Cheng PY, et al. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med. 2012;209(10):1883–1899.
   PubMed Web of Science ®Google Scholar
• Petrova PS, Viller NN, Wong M, et al. TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res. 2017;23(4):1068–1079.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen X, Liu X, et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013;123(5):1999–2010.
   PubMed Web of Science ®Google Scholar
• Vereecque R, Saudemont A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia. 2004;18(7):1223–1230.
   PubMed Web of Science ®Google Scholar
• Daver N. Nivolumab (Nivo) in combination with azacytidine (AZA) in relapsed and frontline elderly acute myeloid leukemia (AML). XXVIII IACRLRD. (Ed.^(Eds). 2017; IACRLRD.
   Google Scholar
• Daver N, Basu S, Garcia-Manero G, et al. Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). Blood. 2016;128(22):763.
   PubMed Web of Science ®Google Scholar
• Daver N. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) or frontline elderly AML. 59th ASH Annual Meeting & Exposition. (Ed.^(Eds). 2017; Atlanta, GA: American Society of Hematology.
   Google Scholar
• Ravandi F. Phase2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia. 59th ASH Annual Meeting & Exposition; (Ed.^(Eds). 2017; Atlanta, GA: American Society of Hematology.
   Google Scholar
• Zeidner JF Phase II study of high dose cytarabine followed by pembrolizumab in relapsed/refractory acute myeloid leukemia (AML). In: 59th ASH Annual Meeting & Exposition. (Ed.^(Eds). 2017; Atlanta, GA: The American Society of Hematology.
   Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044–3051.
   PubMed Web of Science ®Google Scholar
• Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143–153.
   PubMed Web of Science ®Google Scholar
• Vey N.Randomized phase 2 trial of lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the EFFIKIR trial. 59th ASH Annual Meeting & Exposition. (Ed.^(Eds). 2017; Atlanta, GA: American Society of Hematology.
   Google Scholar
• Daver N. Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. 59th ASH Annual Meeting & Exposition. (Ed.^(Eds). 2017; Atlanta, GA: American Society of Hematology.
   Google Scholar
• Daver NG. Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. 2017 ASCO Annual Meeting; (Ed.^(Eds). 2017. J Clin Oncol e18505.
   Google Scholar
• Davids MS. Optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. 59th ASH Annual Meeting & Exposition. (Ed.^(Eds). 2017; Atlanta, GA: American Society of Hematology.
   Google Scholar
• Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162(5):974–986.
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249–253.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–717.
   PubMed Web of Science ®Google Scholar
• Kim S. Th 1/17 cells are expanded in bronchial alveolar lavage (BAL) fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis. 59th ASH Annual Meeting & Exposition. (Ed.^(Eds). 2017; Atlanta, GA: American Society of Hematology.
   Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Andrews A. Treating with checkpoint inhibitors-figure $1 million per patient. Am Health Drug Benefits. 2015;8(Spec Issue):9.
   PubMedGoogle Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–1231.
   PubMed Web of Science ®Google Scholar
• Mangaonkar A, Mondal AK, Fulzule S, et al. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. Sci Rep. 2017;7(1):12892.
   PubMedGoogle Scholar
• Fukuno K, Hara T, Tsurumi H, et al. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. Leuk Lymphoma. 2015;56(5):1398–1405.
   PubMed Web of Science ®Google Scholar
• Mansour I, Zayed RA, Said F, et al. Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia. Hematology. 2016;21(8):447–453.
   PubMed Web of Science ®Google Scholar
• Mabuchi R, Hara T, Matsumoto T, et al. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leuk Lymphoma. 2016;57(1):92–98.
   PubMed Web of Science ®Google Scholar
• Folgiero V, Goffredo BM, Filippini P, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget. 2014;5(8):2052–2064.
   PubMedGoogle Scholar
• Sun H, Li Y, Zhang ZF, et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol. 2015;102(5):579–586.
   PubMed Web of Science ®Google Scholar
• Pyzer AR, Stroopinsky D, Rajabi H, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017;129(13):1791–1801.
   PubMed Web of Science ®Google Scholar
• Jung H. Abstract A90: combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer. Mol Cancer Ther. 2015;14(12 Supplement 2):A90.
   PubMedGoogle Scholar
• Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra267.
   Web of Science ®Google Scholar
• Yang W, Xu Y. Clinical significance of Treg cell frequency in acute myeloid leukemia. Int J Hematol. 2013;98(5):558–562.
   PubMed Web of Science ®Google Scholar
• Sander FE, Nilsson M, Rydström A, et al. Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunol Immunother. 2017;66(11):1473–1484.
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A. 2013;110(44):17945–17950.
   PubMed Web of Science ®Google Scholar
• Xu D, Meng F-Y, Yi Z-S. Role of vascular endothelial growth factor (VEGF) in development and progress of refractory acute myeloid leukemia. Ai Zheng. 2003;22(8):844–848.
   PubMedGoogle Scholar
• Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23(2–3):263–272.
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148.
   PubMed Web of Science ®Google Scholar